- Home
- MARPS vs APM Comparison
MARPS vs APM Comparison
Compare MARPS & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MARPS | APM |
|---|---|---|
| Founded | 1956 | 2010 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0M | 8.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | MARPS | APM |
|---|---|---|
| Price | $4.38 | $0.82 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 34.3K | ★ 66.2K |
| Earning Date | 02-13-2026 | 10-03-2025 |
| Dividend Yield | ★ 8.27% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $965,040.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.39 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.34 | $0.69 |
| 52 Week High | $7.90 | $4.47 |
Technical Indicators
Market Signals| Indicator | MARPS | APM |
|---|---|---|
| Relative Strength Index (RSI) | 43.78 | 41.72 |
| Support Level | $4.44 | $0.80 |
| Resistance Level | $5.21 | $0.88 |
| Average True Range (ATR) | 0.31 | 0.08 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 1.06 | 39.89 |
Price Performance
Historical ComparisonAbout MARPS Marine Petroleum Trust Units of Beneficial Interest
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.